BenevolentAI Results Presentation Deck

BEN-2293: Excellent skin penetration Experimental evidence supports high exposure in human skin at >IC90 free, and low exposure in blood with proposed clinical 1% ointment strength¹. 1% BEN-2293 ointment BID exceeds the exposure needed for PanTrk inhibition in both epidermis/upper dermis and lower dermis even at IC₂0¹ Human in vitro >>IC90 Minipig in vitro >> IC90 Minipig in vivo >IC90 Minipig in vivo Free plasma levels <<400 below IC50 Epidermis and upper dermis Lower Dermis Blood Healthy skin Stratum corneum Stratum granulosum Stratum spinosum Stratum basale Dermis Blood vessel Skin microbiota Staphylococcus aureus. B cell T cell Non-lesional skin IL-18 IL-33 TARC IL-25 MDC TSLP ILC2 cell CLA CCR4 IL-5 IL-13 Lichenification Barrier dysfunction, innate immune system activation and T 2-driven inflammation and/or T 22-driven inflammation Keratinocyte Variable T1 and T, 17 activation CCR10 CRTH2 T2 cell T22 cell Allergen IL-4 IL-13 cell Acute lesional stage FCER1 Eosinophil OX40L H4R T 17 cell IgE IL-4 IL-13 IL-31 Trm cell IL-33 TSLP Cutaneous sensory neuron Chronic lesional stage Langerhans cell Dermal dendritic cell CTA-enabling 28d Tox Package: Rat (IV) and Mini-pig (topical) = Safety margins > 20 fold for AUC and > 269 fold for Cmax to dose limited NOAELS¹ ¹(internal Company drug programme data) IDEC 30

View entire presentation